Online citations, reference lists, and bibliographies.
← Back to Search

Tremelimumab For Patients With Chemotherapy-resistant Advanced Malignant Mesothelioma: An Open-label, Single-arm, Phase 2 Trial.

L. Calabrò, A. Morra, E. Fonsatti, Ornella Cutaia, G. Amato, D. Giannarelli, A. M. Di Giacomo, R. Danielli, M. Altomonte, L. Mutti, M. Maio
Published 2013 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
BACKGROUND Monoclonal antibodies to cytotoxic T-lymphocyte antigen 4 (CTLA4) have therapeutic activity in different tumour types. We aimed to investigate the efficacy, safety, and immunological activity of the anti-CTLA4 monoclonal antibody, tremelimumab, in advanced malignant mesothelioma. METHODS In our open-label, single-arm, phase 2 study, we enrolled patients aged 18 years or older with measurable, unresectable malignant mesothelioma and progressive disease after a first-line platinum-based regimen. Eligible patients had to have a life expectancy of 3 months or more, an Eastern Cooperative Oncology Group performance status of 2 or less, and no history of autoimmune disease. Patients received tremelimumab 15 mg/kg intravenously once every 90 days until progressive disease or severe toxicity. The primary endpoint was the proportion of patients who achieved an objective response (complete or partial response), with a target response rate of 17% according to the modified Response Evaluation Criteria in Solid Tumors (RECIST) for pleural malignant mesothelioma or standard RECIST 1.0 for peritoneal malignant mesothelioma. Analyses were done according to intention to treat. This trial is registered with EudraCT, number 2008-005171-95, and, number NCT01649024. FINDINGS Between May 27, 2009, and Jan 10, 2012, we enrolled 29 patients. All patients received at least one dose of tremelimumab (median two doses, range one to nine). No patients had a complete response and two patients (7%) had a durable partial response (one lasting 6 months and one lasting 18 months); one partial response occurred after initial progressive disease. Thus, the study did not reach its primary endpoint. However, we noted disease control in nine (31%) patients and a median progression-free survival of 6·2 months (95% CI 1·3-11·1) and a median overall survival of 10·7 months (0·0-21·9). 27 patients (93%) had at least one grade 1-2 treatment-emergent adverse event (mainly cutaneous rash, pruritus, colitis, or diarrhoea), and four patients (14%) had at least one grade 3-4 treatment-emergent adverse event (two gastrointestinal, one neurological, two hepatic, and one pancreatic). INTERPRETATION Although the effect size was small in our phase 2 trial, tremelimumab seemed to have encouraging clinical activity and an acceptable safety and tolerability profile in previously treated patients with advanced malignant mesothelioma. FUNDING Associazione Italiana per la Ricerca sul Cancro, Istituto Toscano Tumori, Pfizer, and Fondazione Buzzi Unicem.
This paper references
Management of immune-related adverse events and kinetics of response with ipilimumab.
J. Weber (2012)
Modified RECIST criteria for assessment of response in malignant pleural mesothelioma.
M. Byrne (2004)
Tremelimumab in Combination with Exemestane in Patients with Advanced Breast Cancer and Treatment-Associated Modulation of Inducible Costimulator Expression on Patient T Cells
R. Vonderheide (2010)
Multidisciplinary treatment of malignant pleural mesothelioma.
G. Ceresoli (2007)
Synergistic eff ect of CTLA - 4 blockade and cancer chemotherapy in the induction of anti - tumor immunity
WJ Lesterhuis (2013)
Synergistic Effect of CTLA-4 Blockade and Cancer Chemotherapy in the Induction of Anti-Tumor Immunity
W. Lesterhuis (2013)
Four-year survival update for metastatic melanoma (MM) patients (pts) treated with ipilimumab (ipi) plus dacarbazine (DTIC) on phase 3 study
M Maio
Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme
A. M. Di Giacomo (2013)
Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma.
A. Tarhini (2012)
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey.
P. Zucali (2012)
Advances in malignant mesothelioma.
B. Robinson (2005)
Prolonged upregulation of the expression of HLA class I antigens and costimulatory molecules on melanoma cells treated with 5-aza-2'-deoxycytidine (5-AZA-CdR).
S. Coral (1999)
Improved survival with ipilimumab in patients with metastatic melanoma.
F. S. Hodi (2010)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
J. Wolchok (2009)
Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study
A. Tsao (2012)
Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience.
D. Curran (1998)
What's the place of immunotherapy in malignant mesothelioma treatments?
M. Grégoire (2010)
Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial
B. Carthon (2010)
Five-Year Survival Rates for Patients (PTS) with Metastatic Melanoma (MM) Treated with Ipilimumab (IPI) in Phase II Trials
C. Lebbé (2012)
Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.
A. Hoos (2010)
New Roads Open Up for Implementing Immunotherapy in Mesothelioma
R. Cornelissen (2012)
Modifi ed RECIST criteria for assessment of response in malignant pleural mesothelioma
MJ Byrne (2004)
Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.
T. Lynch (2012)
Clinical studies with anti-CTLA-4 antibodies in non-melanoma indications.
L. Calabrò (2010)
Clinical development of the anti-CTLA-4 antibody tremelimumab.
A. Ribas (2010)
Four-Year Survival Update for Metastatic Melanoma (MM) Patients (PTS) Treated with Ipilimumab (IPI) + Dacarbazine (DTIC) on Phase 3 Study CA184-024
M. Maio (2012)
Safety and effi cacy of combination immunotherapy with interferon alfa - 2 b and tremelimumab in patients with stage IV melanoma
AA Tarhini (2012)
Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy.
M. Callahan (2010)
The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications.
A. M. Di Giacomo (2010)
Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma.
J. Jassem (2008)
Second-line treatment for malignant pleural mesothelioma.
G. Ceresoli (2010)
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
C. Robert (2011)
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.
A. Ribas (2013)
Ipilimumab Increases Activated T Cells and Enhances Humoral Immunity in Patients With Advanced Melanoma
J. Weber (2012)
The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network
Caroline J Voskens (2013)

This paper is referenced by
Advances in Cancer Immunotherapy in Solid Tumors
Smitha P. Menon (2016)
Immunotherapy for malignant mesothelioma: reality check
B. Thapa (2016)
Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis
A. Bertrand (2015)
Systematic review of response rates of sarcomatoid malignant pleural mesotheliomas in clinical trials.
A. Mansfield (2014)
Immune checkpoint blockade in malignant mesothelioma.
Luana Calabrò (2015)
Molecular-Targeted Therapy For Malignant Mesothelioma
Y. Tada (2015)
Human mesothelioma induces defects in dendritic cell numbers and antigen-processing function which predict survival outcomes
S. Cornwall (2016)
Anti-Ma-associated encephalomyeloradiculopathy in a patient with pleural mesothelioma
A. Vogrig (2015)
Surrogate end points for overall survival in trials of PD-(L)1 inhibitors for urinary cancers: a systematic review.
Omar Abdel-Rahman (2018)
[Malignant pleural mesothelioma: new aspects of medical therapy].
S. Kurz (2014)
Nivo-lution in Mesothelioma
A. Mansfield (2019)
Kinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells
Elliott J Brea (2016)
Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients
E. Marcq (2017)
Current issues in malignant pleural mesothelioma evaluation and management.
J. Ai (2014)
BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma
Raunak Shrestha (2019)
Emerging immunotherapy for the treatment of esophageal cancer
SeungJu Jackie Oh (2016)
CTLA-4 in mesothelioma patients: tissue expression, body fluid levels and possible relevance as a prognostic factor
S. Roncella (2016)
Systemic Approach to Malignant Pleural Mesothelioma: What News of Chemotherapy, Targeted Agents and Immunotherapy?
D. Signorelli (2016)
Immunotherapy of Malignant Peritoneal Mesothelioma and Pseudomyxoma Peritonei
Irina Zh. Zhubina (2019)
Processing Escapes: A New Perspective on Immune Escape Mechanisms
F. Mairinger (2017)
Tailoring cells for clinical needs: Meeting report from the Advanced Therapy in Healthcare symposium (October 28–29 2017, Doha, Qatar)
Sara Deola (2018)
Anti-TIM-3 Antibody Prevents Lymphocyte Apoptosis and Enhances Dendritic Cell Cancer Therapy
Eiichi Hayashi (2015)
Building a Bridge between Chemotherapy and Immunotherapy in Malignant Pleural Mesothelioma: Investigating the Effect of Chemotherapy on Immune Checkpoint Expression
Elly Marcq (2019)
Drug resistance in cancer immunotherapy: new strategies to improve checkpoint inhibitor therapies
Jesús Rodríguez-Pascual (2019)
Immune checkpoint inhibitors in malignant pleural mesothelioma: promises and challenges
G. Ceresoli (2016)
The Role of Surgery in Malignant Pleural Mesothelioma
Levon Toufektzian (2015)
Novel insights into the pathophysiology and treatment of malignant pleural mesothelioma
Alistair M. Cook (2015)
Coinhibitory Pathways in Immunotherapy for Cancer.
S. Baumeister (2016)
Le mésothéliome : maladie orpheline ?
L. Greillier (2016)
[Immunotherapy in non-small cell lung cancer: inhibition of PD1/PDL1 pathway].
L. Guilleminault (2015)
Immune-Related Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitors
Sabina Sandigursky (2018)
Malignant Mesothelioma: Has Anything Changed?
Roger Y Kim (2019)
See more
Semantic Scholar Logo Some data provided by SemanticScholar